CAS 211096-49-0: N-(2-Bromophenyl)-N'-(4-cyano-1H-1,2,3-benzotriazol-7-yl)urea

SB-265610 is a selective inhibitor of the EGF receptor, which binds to the epidermal growth factor (EGF) receptor. SB-265610 prevents the binding of EGF to its receptor, thereby inhibiting tumor cell proliferation and inducing apoptosis. SB-265610 has been shown to inhibit angiogenic factors and cause an antimicrobial effect in breast cancer cells by blocking the CXCR2 chemokine receptors. It also increases the amount of time before atherosclerotic lesions progress to heart disease or cardiac death.

SB-265610 (GSK-CXCR2) is a nonpeptide and allosteric CXCR2 antagonist.

SB-265610